Major Investors Exit $6.3 Billion Stake in Galderma Amid Record Swiss Sale

A consortium of institutional investors has divested their entire $6.3 billion stake in Galderma, a leading global dermatology company, in a transaction that set a new benchmark for private equity exits in Switzerland. The sale, finalized in early March 2026, represents one of the largest healthcare-related divestments in the country's recent history and reflects a strategic realignment by major shareholders seeking to redeploy capital amid shifting market dynamics. The exit comes amid increased scrutiny of high-multiple valuations in specialty pharma, particularly in niche dermatological treatments. Galderma, which operates under a joint venture between L’Oréal and private equity firm KKR, has seen its valuation peak in recent years, driven by strong revenue growth in products like Botox-like injectables and acne therapeutics. However, the $6.3 billion exit value signals a potential reassessment of long-term growth assumptions, especially in light of rising R&D costs and competitive pressures from generic alternatives. The divestment has immediate ripple effects across related markets. Shares of Galderma’s parent entity, GALD, experienced a 3.2% decline in after-hours trading on the Swiss Exchange (SWX), while healthcare ETFs such as XLV saw a 0.7% dip as investors repositioned holdings. Additionally, the move has drawn attention to the broader HCL (Healthcare) sector, where several biotech firms with similar market caps are under review for potential revaluation. Market analysts note that while the exit is not indicative of systemic risk, it may prompt caution among investors eyeing high-growth healthcare plays. The transaction highlights a growing preference for liquidity and capital efficiency over long-term holdings in mature specialty pharma businesses, particularly in Europe.